Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response — HIPCVAX-010S  

Influenza A Subtype H5N1 Infection Clinical Trial

Official title: Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Status Completed

Clinical Trial Summary

The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the AS03 adjuvant.

Clinical Trial Description

Influenza, caused by the influenza virus, is a contagious respiratory disease that can result in mild to severe illness. It is estimated that up to 80,000 deaths and approximately 200,000 Americans are hospitalized annually due to complications. Vaccination is the most effective way of controlling flu and preventing its illness and complications; however, antibody responses to seasonal influenza vaccines decrease over time and only target a small number of antibody binding sites In 2015, the Hope Clinic of the Emory Vaccine Center completed a study analyzing human immune responses to a pandemic H5N1, or "bird flu" vaccine, either alone or combined with the GlaxoSmithKline adjuvant system 03 (AS03).

Participants that took part in the 2013 HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with and without AS03 Adjuvant study will be enrolled in this study to assess the effect of seasonal influenza vaccine in shaping the immune responses. The study aims to address important immunological mechanisms that can assist scientists in the creation of a universal influenza vaccine. ;

Related Conditions & MeSH terms

• Influenza A Subtype H5N1 Infection
• Influenza, Human

• NCT number: NCT03701061
• Study type: Interventional
• Source: Emory University
• Status: Completed
• Phase: Phase 4
• Start date: October 11, 2018
• Completion date: January 31, 2020